AstraZeneca Plc (AZN)

38.34
0.11 0.29
NYSE : Health Technology
Prev Close 38.23
Open 38.48
Day Low/High 38.19 / 38.53
52 Wk Low/High 32.69 / 41.77
Volume 1.36M
Avg Volume 4.42M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 96.54B
EPS 1.20
P/E Ratio 17.20
Div & Yield 1.37 (3.50%)

Latest News

AstraZeneca Presents Clinical Research Advances For Blood Cancer Patients At 2018 American Society Of Hematology Annual Meeting

AstraZeneca Presents Clinical Research Advances For Blood Cancer Patients At 2018 American Society Of Hematology Annual Meeting

AstraZeneca, together with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American...

FARXIGA Significantly Reduced Hospitalization For Heart Failure Or CV Death In A Broad Patient Population With Type 2 Diabetes In The Landmark DECLARE-TIMI 58 Trial

FARXIGA Significantly Reduced Hospitalization For Heart Failure Or CV Death In A Broad Patient Population With Type 2 Diabetes In The Landmark DECLARE-TIMI 58 Trial

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin).

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial Of FARXIGA In Patients With Type 2 Diabetes To Be Featured At AHA 2018

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial Of FARXIGA In Patients With Type 2 Diabetes To Be Featured At AHA 2018

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2...

Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

AstraZeneca To Present New Data Demonstrating Breadth Of Research Portfolio In Renal Disease At ASN Kidney Week 2018

AstraZeneca To Present New Data Demonstrating Breadth Of Research Portfolio In Renal Disease At ASN Kidney Week 2018

AstraZeneca will present new research spanning the Company's Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, October 23-28, 2018.

(Graphic: Business Wire)

(Graphic: Business Wire)

AstraZeneca and Merck & Co., Inc.

IMFINZI® (durvalumab) Is The First Immunotherapy To Demonstrate Significant Overall Survival Benefit In Unresectable, Stage III Lung Cancer

IMFINZI® (durvalumab) Is The First Immunotherapy To Demonstrate Significant Overall Survival Benefit In Unresectable, Stage III Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI ® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on...

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine In The US For 2018-2019 Flu Season

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine In The US For 2018-2019 Flu Season

AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season.

FARXIGA Achieved A Positive Result In The Phase III DECLARE-TIMI 58 Trial, A Large Cardiovascular Outcomes Trial In 17,000 Patients With Type 2 Diabetes

FARXIGA Achieved A Positive Result In The Phase III DECLARE-TIMI 58 Trial, A Large Cardiovascular Outcomes Trial In 17,000 Patients With Type 2 Diabetes

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date.

FASENRA (benralizumab) Shows Consistent Safety And Sustained Efficacy In Long-Term Phase III BORA Trial In Severe Eosinophilic Asthma

FASENRA (benralizumab) Shows Consistent Safety And Sustained Efficacy In Long-Term Phase III BORA Trial In Severe Eosinophilic Asthma

AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed...

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

US FDA Approves LUMOXITI™ (moxetumomab Pasudotox-tdfk) For Certain Patients With Relapsed Or Refractory Hairy Cell Leukemia

US FDA Approves LUMOXITI™ (moxetumomab Pasudotox-tdfk) For Certain Patients With Relapsed Or Refractory Hairy Cell Leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or...

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients

Novice Trade: EWU United Kingdom ETF

Novice Trade: EWU United Kingdom ETF

This at-the-money, long put shooter is a high risk trade, so use discretionary capital.

Novice Trade: EWU ETF

Novice Trade: EWU ETF

This portfolio cannot be trusted to be diversified enough.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

FARXIGA In Combination With ONGLYZA Demonstrates Similar Glycemic Control With Additional Benefits Vs. Insulin Glargine In Patients With Type 2 Diabetes

FARXIGA In Combination With ONGLYZA Demonstrates Similar Glycemic Control With Additional Benefits Vs. Insulin Glargine In Patients With Type 2 Diabetes

AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA ® (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June...

AstraZeneca To Share Latest Data From An Industry-Leading Portfolio That Aims To Advance Clinical Understanding Of Diabetes And CV Risk Management At ADA 2018

AstraZeneca To Share Latest Data From An Industry-Leading Portfolio That Aims To Advance Clinical Understanding Of Diabetes And CV Risk Management At ADA 2018

AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company's Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American...

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.

Jim's Daily Rundown

Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!

TheStreet Quant Rating: B (Buy)